SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts give SAB Biotherapeutics a “Moderate Buy” consensus: Nine of 11 analysts rate the stock a buy, while one rates it a hold and one a sell. The average 12-month price target is $12.00, well above the reported $3.22 share price.
• SABS reported quarterly earnings of -$0.28 per share, in line with consensus, and analysts expect a full-year loss of $1.17 per share. The stock has traded between $1.85 and $5.15 over the past year.
• Institutional interest has increased, including a 700.8% expansion of Perceptive Advisors’ position; hedge funds and other institutions collectively own 7.82% of the company. SAB is a clinical-stage biotech developing fully human polyclonal antibody therapies using its DiversitAb platform.

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.00.

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Wall Street Zen raised SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 10th. Weiss Ratings upgraded SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 17th. Barclays started coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an "overweight" rating and a $13.00 price objective on the stock. Finally, Leerink Partners upped their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, June 15th.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $3.22 on Wednesday. The stock has a market capitalization of $292.99 million, a price-to-earnings ratio of -2.48 and a beta of 0.53. SAB Biotherapeutics has a 12 month low of $1.85 and a 12 month high of $5.15. The firm's 50 day simple moving average is $3.62 and its 200-day simple moving average is $3.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). Analysts expect that SAB Biotherapeutics will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SABS. Perceptive Advisors LLC grew its holdings in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of SAB Biotherapeutics in the 1st quarter valued at approximately $1,915,000. AWM Investment Company Inc. acquired a new stake in shares of SAB Biotherapeutics during the 2nd quarter worth approximately $1,462,000. Propel Bio Management LLC acquired a new position in SAB Biotherapeutics in the fourth quarter valued at approximately $2,442,000. Finally, DV Trading LLC acquired a new stake in SAB Biotherapeutics during the first quarter worth $1,532,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing targeted antibody-based medicines for infectious diseases and immune-mediated conditions. The company's approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB's technology platform, known as DiversitAb, uses genetically engineered cattle that are capable of producing human antibodies. Antibodies harvested from the animals' plasma are evaluated for potential use as therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.